Cypress Semiconductor Introduces Industry's First QDR and DDR SRAM Devices on 65-nm Linewidth

Cypress Semiconductor Corp. (NYSE:CY), an industry leader in SRAMs, today announced it is sampling the industry's first Quad Data Rate™ (QDR™) and Double Data Rate (DDR) SRAM devices on 65-nm linewidth. The new 72-Mbit QDRII, QDRII+, DDRII and DDRII+ memories leverage process technology developed with foundry partner UMC. The new SRAMs feature the market's fastest available clock speed of 550 MHz and a total data rate of 80 Gbps in a 36-bit I/O width QDRII+ device, using half the power of 90-nm SRAMs. They are ideal for networking applications, including Internet core and edge routers, fixed and modular Ethernet switches, 3G base stations and secure routers, and also enhance the performance of medical imaging and military signal processing systems. The devices are pin compatible with 90-nm SRAMs, enabling networking customers to increase performance and port density while maintaining the same board layout.

Compared with their 90-nm predecessors, the 65-nm QDR and DDR SRAMs lower input and output capacitance by 60 percent. The QDRII+ and DDRII+ devices have On-Die Termination (ODT), which improves signal integrity, reduces system cost and saves board space by eliminating external termination resistors. The 65-nm devices use a Phase Locked Loop (PLL) instead of a Delay Locked Loop (DLL), which enables a 35 percent wider data valid window to reduce development time and cost for the customer.

“We continue to expand our Synchronous SRAM portfolio to broaden our target markets and grow market share,” said Dana Nazarian, Executive Vice President of the Memory and Imaging Division at Cypress. “Cypress is committed to supporting the SRAM market long-term and building on our leadership position.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.